VBLT News and Press, Vascular Biogenics Ltd. From 05/12/20

TEL AVIV, Israel, May 12, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that it has closed the previously announced registered direct offering of 6,349,208 ordinary shares of the Company, at a purchase price of $1.575 per share, in a registered direct offeri...

Gainers:  Tetraphase Pharmaceuticals (NASDAQ: TTPH ) +90% . More news on: Tetraphase Pharmaceuticals, Inc., ION Geophysical Corporation, Twilio Inc., Stocks on the move, , Read more ...

VBL Therapeutics ( VBLT -18.4% ) is in the red in early trade in response to its agreements with institutional investors for the direct placement of ~6.3M ordinary shares at $1.575 per share. More news on: Vascular Biogenics Ltd., Healthcare stocks news, , Stocks on the move, Read ...

TEL AVIV, Israel, May 07, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale of 6,349,208 ordinary shares of the Company, at a purchase price of $1.575 p...

Study was rated in the top 10% of all abstracts in this category and was selected as Poster of Distinction Data demonstrate the potential of VBL's proprietary MOSPD2 mAbs for chronic inflammatory indications, via a novel and distinct mechanism targeting monocyte migration TEL AVIV...

TEL AVIV, Israel, May 04, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio ...

TEL AVIV, Israel, May 04, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ) is pleased to announce the publication of a new manuscript demonstrating the potential of MOSPD2 antibodies for Multiple Sclerosis (MS). VBL's data offer a differentiated approach to potential treatment o...

VBL Therapeutics (NASDAQ: VBLT ) has been awarded a non-dilutive grant of up to NIS3.175M (~$0.9M) by the Israel Innovation Authority. More news on: Vascular Biogenics Ltd., Healthcare stocks news, Stocks on the move, Read more ...

TEL AVIV, Israel, April 21, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that it has been awarded a non-dilutive grant of up to 3.175 million New Israeli Shekels (NIS) (approximately $0.9 million) by the Israel Innovation Authority (IIA). The IIA h...

TEL AVIV, Israel, April 06, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), announced today that it has reached a milestone event under its collaborative agreement with a world-leading European animal health company, evaluating use of VB-201 for veterinary applications. Upon rea...